Manager TitleAgeSince
Chief Executive Officer 54 07/04/2026
Chief Tech/Sci/R&D Officer - 01/09/2024
Chief Tech/Sci/R&D Officer - 01/09/1999
Director TitleAgeSince
Director/Board Member 54 19/12/2025
Date Insider Type Main position Quantity % Market Cap.
16/06/23Free

Chief Financial Officer

28,866 0.0568%
19/04/23Others

Chief Executive Officer

400,000 0.7936%
05/12/22Fiscal year

Chief Financial Officer

125,000 0.2492%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.15% - - 886M
-0.91%+1.46%+73.50%+129.01% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.69%+4.90%+43.96%-26.76% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-6.73%+9.90%+36.04% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average -0.72%+5.15%+55.65%+149.88% 26.96B
Weighted average by Cap. -1.16%+2.58%+57.58%+139.31%
Logo Ergomed
Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.
Employees
1,500
  1. Stock Market
  2. Stocks
  3. ERGO Stock